telangiectasias

Dr. Jean Bolognia presented information about antibody-drug conjugates (ADCs), including enfortumab vedotin, trastuzumab emtansine, trastuzumab deruxtecan, and loncastuximab tesirine. ADCs are monoclonal antibodies (mAbs) combined with a chemotherapeutic agent via a linker. They are associated with cutaneous side effects that dermatologists need to know about.  First, Bolognia explained the nomenclature of ADCs. The first part…